来迪派韦-索磷布韦在12-17岁基因1型丙型肝炎病毒感染青少年中的安全性和有效性
这项2期、多中心、开放标签研究评估了来迪派韦-索磷布韦治疗12-17岁慢性丙型肝炎病毒基因1型感染青少年的疗效和安全性。100例患者接受90 mg来迪派韦和400 mg索磷布韦复方片每日一次治疗12周,98%(98/100;95%CI 93%-100%)达到持续病毒学应答。最常见不良事件为头痛(27%)、腹泻(14%)和疲劳(13%),无严重不良事件报告。
要点
- 98%(98/100;95%CI 93%-100%)的青少年患者达到治疗结束后12周持续病毒学应答。
- 无患者出现病毒学失败;2例未达到持续病毒学应答者分别在治疗期间或治疗后失访。
- 最常见不良事件为头痛(27%)、腹泻(14%)和疲劳(13%),无严重不良事件报告。
核心结论
- 来迪派韦-索磷布韦治疗青少年慢性丙型肝炎病毒基因1型感染高度有效;目前用于成人的来迪派韦-索磷布韦剂量在青少年中耐受良好,并具有适当的药代动力学特征。
研究设计与样本
- 2期、多中心、开放标签研究,纳入100例12-17岁慢性丙型肝炎病毒基因1型感染患者,接受90 mg来迪派韦和400 mg索磷布韦复方片每日一次治疗12周。
- 开始给药后第10天,10例患者接受了索磷布韦、来迪派韦及索磷布韦代谢物GS-331007浓度的密集药代动力学评估。
主要发现
- 患者中位年龄15岁(范围12-17),80%为初治患者,84%经围产期传播感染;1例有肝硬化,42例无肝硬化,57例纤维化程度未知。
- 98%(98/100;95%CI 93%-100%)的患者达到治疗结束后12周持续病毒学应答,无患者出现病毒学失败;2例未达到持续病毒学应答者分别在治疗期间或治疗后失访。
- 最常报告的不良事件为头痛(27%)、腹泻(14%)和疲劳(13%),无严重不良事件报告。
- 索磷布韦、来迪派韦和GS-331007的浓度-时间曲线下面积(tau)和最大浓度值与来迪派韦和索磷布韦2期和3期研究中的成人相比,均在预设的药代动力学等效界限50%-200%之内。
局限性
- 2例未达到持续病毒学应答者分别在治疗期间或治疗后失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: No all-oral, direct-acting antiviral regimens have been approved for children with chronic hepatitis C virus (HCV) infection. We conducted a phase 2, multicenter, open-label study to evaluate the efficacy and safety of ledipasvir-sofosbuvir in adolescents with chronic HCV genotype 1 infection. One hundred patients aged 12-17 years received a combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir once daily for 12 weeks. On the tenth day following initiation of dosing, 10 patients underwent an intensive pharmacokinetic evaluation of the concentrations of sofosbuvir, ledipasvir, and the sofosbuvir metabolite GS-331007. The primary efficacy endpoint was the percentage of patients with a sustained virologic response at 12 weeks posttreatment. Median age of patients was 15 years (range 12-17). A majority (80%) were HCV treatment-naive, and 84% were infected through perinatal transmission. One patient had cirrhosis, and 42 did not; in 57 patients the degree of fibrosis was unknown. Overall, 98% (98/100; 95% confidence interval 93%-100%) of patients reached sustained virologic response at 12 weeks. No patient had virologic failure. The 2 patients who did not achieve sustained virologic response at 12 weeks were lost to follow-up either during or after treatment. The three most commonly reported adverse events were headache (27% of patients), diarrhea (14%), and fatigue (13%). No serious adverse events were reported. Area under the concentration-time curve (tau) and maximum concentration values for sofosbuvir, ledipasvir, and GS-331007 were within the predefined pharmacokinetic equivalence boundaries of 50%-200% when compared with adults from phase 2 and 3 studies of ledipasvir and sofosbuvir. CONCLUSION: Ledipasvir-sofosbuvir was highly effective at treating adolescents with chronic HCV genotype 1 infection; the dose of ledipasvir-sofosbuvir currently used in adults was well tolerated in adolescents and had an appropriate pharmacokinetic profile. (Hepatology 2017;66:371-378).
引用
- Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017. PMID: 27997679. doi:10.1002/hep.28995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。